Akero Therapeutics (Akero Therapeutics) EBIT

: $-148.66 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

Akero Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-54.29 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-148.66 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Akero Therapeutics's annualized ROC % for the quarter that ended in Dec. 2023 was -565.93%. Akero Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -20,544.56%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Akero Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -15.94%.

Akero Therapeutics EBIT Historical Data

The historical data trend for Akero Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akero Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-45.65

-80.15

-100.78

-111.29

-148.66

Akero Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-22.70	-25.37	-30.23	-38.77	-54.29

Competitive Comparison

For the Biotechnology subindustry, Akero Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akero Therapeutics EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, Akero Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Akero Therapeutics's EV-to-EBIT falls into.

Akero Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-148.66 Mil.

Akero Therapeutics (NAS:AKRO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Akero Therapeutics's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-247.492 * ( 1 - 0% )	/	( (65.337	+	22.127)	/ 2 )
=	-247.492	/	43.732
=	-565.93 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	635.331	-	22.462	-	( 554.732	-	max(0, 28.447	-	575.979	+	554.732	))
=	65.337

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	580.271	-	17.31	-	( 550.01	-	max(0, 19.128	-	559.962	+	550.01	))
=	22.127

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Akero Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-217.156	/	( ( (1.088 + max(-4.6189999999999, 0))	+	(1.026 + max(-8.654, 0)) )	/	2 )
=	-217.156	/	( ( 1.088	+	1.026 )	/	2 )
=	-217.156	/	1.057
=	-20,544.56 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	21.247)	-	(22.462	+	0	+	3.404)
=	-4.6189999999999

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	9.952)	-	(17.31	+	0	+	1.296)
=	-8.654

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Akero Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-148.66	/	932.811
	=	-15.94 %

Akero Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Akero Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Akero Therapeutics (Akero Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akero Therapeutics Inc (NAS:AKRO) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

0K4:Germany 0K4:Germany

Address

601 Gateway Boulevard, Suite 350, South San Francisco, CA, USA, 94080

Website

https://www.akerotx.com

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Executives

Jonathan Young	officer: Chief Operating Officer	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FL, SOUTH SAN FRANCISCO CA 94080
Andrew Cheng	director, officer: President & CEO	170 HARBOR WAY, 3RD FLOOR, C/O AKERO THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Catriona Yale	officer: Chief Development Officer	C/O AKERO THERAPEUTICS INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
William Richard White	officer: Chief Financial Officer	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Timothy Rolph	officer: Chief Scientific Officer	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY, 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
G. Walmsley Graham	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Tomas J. Heyman	director	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Jane Henderson	director	C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Patrick Lamy	officer: See Remarks	AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Skorpios Trust	other: Former 10% owner	195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Montrago Trustees Ltd	other: Former 10% owner	195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Blue Horizon Enterprise Ltd	other: Former 10% owner	3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Ezbon International Ltd	other: Former 10% owner	3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Seth Loring Harrison	director	230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Chou Judy	director	C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BLVD, SUITE 350, SOUTH SAN FRANCISCO CA 64080